Clinical Research Directory
Browse clinical research sites, groups, and studies.
SPGL008 in Combination With SSGJ-706 ± Chemotherapy for Advanced Non-small Cell Lung Cancer
Sponsor: Shenyang Sunshine Pharmaceutical Co., LTD.
Summary
This study is an open, multicenter, phase 2 clinical trial of SPGL008 in combination with SSGJ-706 ± chemotherapy for the treatment of advanced non-small cell lung cancer. The objective is to evaluate the safety and efficacy of SPGL008 combined with SSGJ-706 in participants with driver gene-negative advanced non-small cell lung cancer.
Official title: A Phase 2 Study of SPGL008 in Combination With SSGJ-706 ± Chemotherapy for Advanced Non-small Cell Lung Cancer
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
220
Start Date
2026-11
Completion Date
2029-11
Last Updated
2026-10-15
Healthy Volunteers
No
Conditions
Interventions
SSGJ-706
SSGJ-706 is a bispecific antibody that targets both human PD-1 and PD-L1
SPGL008
SPGL008 is a dual-functional molecule that combines an anti-B7-H3 monoclonal antibody with IL-15Rα sushi / IL-15.
Chemotherapy
Chemotherapy